That is evidence being collected by the manufacturer as part of their post-market surveillance, and it's a post-market registry.
We're suggesting that, in fact, we should not set up a separate registry, which is what has happened as a result of this agreement, and that we should all be part of this international registry, because that's where you're going to get the bulk of the information to know whether these drugs are safe and effective. Unfortunately, again, because we were dealing in isolation, separate from what's happening in the international community, we've ended up with what I consider to be, quite frankly, a very expensive exercise--a time-delayed exercise, because there had to be a research protocol and it had to go to each one of the five central hospitals to be approved. I mean, two and a half years later, we're only getting our very first patients enrolled under that research protocol, and the evidence that will come out of it will actually have no real benefit because it is not part of the international registry.